Roivant Sciences is trading 4.07% down at $36.05 after opening-day weakness on August 28, 2026.
- The FDA approval of LISRAYA for adult dermatomyositis was announced August 27.
- An investor call was scheduled for 8:00 a.m. Eastern on August 28.
- Available reporting does not establish that the approval, launch pricing, or call directly caused the decline; broader indexes were nearly flat.